M&A Deal Summary

SOBI Acquires Dova Pharmaceuticals

On September 30, 2019, SOBI acquired life science company Dova Pharmaceuticals for 915M USD

Acquisition Highlights
  • This is SOBI’s 2nd transaction in the Life Science sector.
  • This is SOBI’s 2nd largest (disclosed) transaction.
  • This is SOBI’s 1st transaction in the United States.
  • This is SOBI’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2019-09-30
Target Dova Pharmaceuticals
Sector Life Science
Buyer(s) SOBI
Deal Type Add-on Acquisition
Deal Value 915M USD

Target

Dova Pharmaceuticals

Durham, North Carolina, United States
Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

SOBI

Stockholm 

, Sweden
Category Company
Founded 1939
Sector Life Science
Employees1,772
Revenue 22.1B SEK (2023)
DESCRIPTION

SOBI is an integrated biopharmaceutical company with an international market presence, developing and commercializing pharmaceuticals for patients with rare diseases. SOBI was founded in 1939 and is headquartered in Solna, Sweden.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 3 of 4
State (North Carolina) 1 of 1
Country (United States) 1 of 2
Year (2019) 1 of 1
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-11-05 Swedish Orphan International

Sweden

Swedish Orphan International engages in the research, development, production, distribution, and marketing of specialty pharmaceuticals.

Buy kr3.5B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-05-10 CTI BioPharma

Seattle, Washington, United States

CTI is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI BioPharma was founded in 1991 and is based in Seattle, Washington.

Buy $1.7B
Mergr

Product

Company

Legal